Piper Jaffray analyst David Amsellem raised his price target for Neurocrine Biosciences to $153 from $116 saying the shares still offer "ample runway for significant value creation" despite the 60% rally year-to-date. Though the ramp of Orilissa has not been as strong as hoped, there remains "ample runway" for continued aggressive Ingrezza growth in tardive dyskinesia along with the potential for additional contribution from chorea associated with Huntington's disease, a relatively low-risk expansion indication, Amsellem tells investors in a research note. The analyst reiterates an Overweight rating on Neurocrine shares.